Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 9, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms.

Mary Beth Beasley1, Yasushi Yatabe2, Mauro Papotti3

  • 1Department of Pathology, Ichan School of Medicine at Mount Sinai, New York, NY.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|June 7, 2026
PubMed
Summary

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026
Same author

In Reply.

Archives of pathology & laboratory medicine·2026
Same author

Progress in Thymic Malignancy Care: The Imperative for Global Standards and Collaboration.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Pulmonary venoocclusive disease/pulmonary capillary hemangiomatosis: Inadequacy of clinico-radiologic features in diagnosis.

Human pathology·2026

This study proposes an updated classification for pulmonary neuroendocrine neoplasms (NENs), incorporating Ki-67 as a diagnostic criterion and recognizing "carcinoid/NET G3." This aims for precise stratification and targeted therapies for lung neuroendocrine tumors (NETs).

Area of Science:

  • Pulmonary Oncology
  • Histopathology
  • Molecular Pathology

Background:

  • The 2021 WHO classification of thoracic tumors provides a foundation for understanding pulmonary neuroendocrine neoplasms (NENs).
  • Recent advances in molecular pathways and histopathological analysis necessitate an update to the existing classification system.
  • Pulmonary NENs require precise stratification for effective therapeutic strategies.

Purpose of the Study:

  • To propose a revised classification for pulmonary carcinoid/neuroendocrine tumors (NETs) based on current scientific knowledge.
  • To refine diagnostic criteria and terminology for pulmonary NENs.
  • To facilitate accurate tumor categorization and guide the development of subtype-specific treatments.

Main Methods:

  • Comprehensive review of the current pulmonary NEN landscape by a multidisciplinary expert panel.
Keywords:
Pulmonary neuroendocrine neoplasmcarcinoid tumorclassificationlarge cell neuroendocrine carcinomaneuroendocrine carcinomapulmonary neuroendocrine tumorsmall cell lung cancer

Related Experiment Videos

Last Updated: Jun 9, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

  • Deliberation on modifications to the 2021 WHO classification.
  • Proposal of a new classification framework incorporating key diagnostic updates.

    • Main Results:

    • The proposed classification shifts towards broader adoption of "NET" nomenclature while retaining "carcinoid" for clinical communication.
    • Ki-67 is integrated as a diagnostic criterion, aligning with international NET classification practices.
    • Formal recognition of "carcinoid/NET G3" as a distinct subtype with specific proliferative and molecular features.

    Conclusions:

    • The proposed classification enhances the precise stratification of pulmonary NENs.
    • Incorporating Ki-67 and recognizing "carcinoid/NET G3" aids in accurate tumor categorization.
    • This updated framework supports the development of novel, subtype-specific therapeutic strategies for lung neuroendocrine tumors.